Boag Stephen E, Das Rajiv, Shmeleva Evgeniya V, Bagnall Alan, Egred Mohaned, Howard Nicholas, Bennaceur Karim, Zaman Azfar, Keavney Bernard, Spyridopoulos Ioakim
J Clin Invest. 2015 Aug 3;125(8):3063-76. doi: 10.1172/JCI80055. Epub 2015 Jul 13.
Lymphocytes contribute to ischemia/reperfusion (I/R) injury in several organ systems, but their relevance in ST elevation myocardial infarction (STEMI) is unknown. Our goal was to characterize lymphocyte dynamics in individuals after primary percutaneous coronary intervention (PPCI), assess the prognostic relevance of these cells, and explore mechanisms of lymphocyte-associated injury.
Lymphocyte counts were retrospectively analyzed in 1,377 STEMI patients, and the prognostic relevance of post-PPCI lymphopenia was assessed by Cox proportional hazards regression. Blood from 59 prospectively recruited STEMI patients undergoing PPCI was sampled, and leukocyte subpopulations were quantified. Microvascular obstruction (MVO), a component of I/R injury, was assessed using MRI.
In the retrospective cohort, lymphopenia was associated with a lower rate of survival at 3 years (82.8% vs. 96.3%, lowest vs. highest tertile; hazard ratio 2.42). In the prospective cohort, lymphocyte counts fell 90 minutes after reperfusion, primarily due to loss of T cells. CD8+ T cells decreased more than CD4+ T cells, and effector subsets exhibited the largest decline. The early decrease in effector T cell levels was greater in individuals that developed substantial MVO. The drop in T cell subsets correlated with expression of the fractalkine receptor CX3CR1 (r2 = 0.99, P = 0.006). Serum fractalkine concentration peaked at 90 minutes after reperfusion, coinciding with the T cell count nadir.
Lymphopenia following PPCI is associated with poor prognosis. Our data suggest that fractalkine contributes to lymphocyte shifts, which may influence development of MVO through the action of effector T cells.
Not applicable.
British Heart Foundation (FS/12/31/29533) and National Institute of Health Research (NIHR) Newcastle Biomedical Research Centre.
淋巴细胞在多个器官系统的缺血/再灌注(I/R)损伤中起作用,但其在ST段抬高型心肌梗死(STEMI)中的相关性尚不清楚。我们的目标是描述直接经皮冠状动脉介入治疗(PPCI)后个体的淋巴细胞动态变化,评估这些细胞的预后相关性,并探讨淋巴细胞相关损伤的机制。
对1377例STEMI患者的淋巴细胞计数进行回顾性分析,并通过Cox比例风险回归评估PPCI后淋巴细胞减少的预后相关性。采集了59例接受PPCI的前瞻性招募的STEMI患者的血液,对白细胞亚群进行定量分析。使用磁共振成像(MRI)评估I/R损伤的一个组成部分微血管阻塞(MVO)。
在回顾性队列中,淋巴细胞减少与3年生存率较低相关(82.8%对96.3%,最低三分位数对最高三分位数;风险比2.42)。在前瞻性队列中,再灌注90分钟后淋巴细胞计数下降,主要是由于T细胞减少。CD8+T细胞的减少比CD4+T细胞更多,效应子亚群下降幅度最大。发生大量MVO的个体中效应T细胞水平的早期下降更大。T细胞亚群的下降与趋化因子受体CX3CR1的表达相关(r2 = 0.99,P = 0.006)。血清趋化因子浓度在再灌注后90分钟达到峰值,与T细胞计数最低点一致。
PPCI后淋巴细胞减少与预后不良相关。我们的数据表明趋化因子导致淋巴细胞转移,这可能通过效应T细胞的作用影响MVO的发生。
不适用。
英国心脏基金会(FS/12/31/29533)和国家卫生研究院(NIHR)纽卡斯尔生物医学研究中心。